Literature DB >> 34361064

PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases.

Hugo Christian Monroy-Ramirez1, Marina Galicia-Moreno1, Ana Sandoval-Rodriguez1, Alejandra Meza-Rios2, Arturo Santos2, Juan Armendariz-Borunda1,2.   

Abstract

Carbohydrates and lipids are two components of the diet that provide the necessary energy to carry out various physiological processes to help maintain homeostasis in the body. However, when the metabolism of both biomolecules is altered, development of various liver diseases takes place; such as metabolic-associated fatty liver diseases (MAFLD), hepatitis B and C virus infections, alcoholic liver disease (ALD), and in more severe cases, hepatocelular carcinoma (HCC). On the other hand, PPARs are a family of ligand-dependent transcription factors with an important role in the regulation of metabolic processes to hepatic level as well as in other organs. After interaction with specific ligands, PPARs are translocated to the nucleus, undergoing structural changes to regulate gene transcription involved in lipid metabolism, adipogenesis, inflammation and metabolic homeostasis. This review aims to provide updated data about PPARs' critical role in liver metabolic regulation, and their involvement triggering the genesis of several liver diseases. Information is provided about their molecular characteristics, cell signal pathways, and the main pharmacological therapies that modulate their function, currently engaged in the clinic scenario, or in pharmacological development.

Entities:  

Keywords:  hepatic damage; metabolic alterations; nuclear factors; pharmacological targets

Year:  2021        PMID: 34361064     DOI: 10.3390/ijms22158298

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  7 in total

Review 1.  Host cell proteins modulated upon Toxoplasma infection identified using proteomic approaches: a molecular rationale.

Authors:  Sajad Rashidi; Carmen Vieira; Reza Mansouri; Mohammad Ali-Hassanzadeh; Esmaeel Ghani; Mohammadreza Karimazar; Paul Nguewa; Raúl Manzano-Román
Journal:  Parasitol Res       Date:  2022-05-13       Impact factor: 2.289

2.  Endocannabinoid-Binding Receptors as Drug Targets.

Authors:  María Gómez-Cañas; Carmen Rodríguez-Cueto; Valentina Satta; Inés Hernández-Fisac; Elisa Navarro; Javier Fernández-Ruiz
Journal:  Methods Mol Biol       Date:  2023

3.  PPARs as Key Mediators in the Regulation of Metabolism and Inflammation.

Authors:  Manuel Vázquez-Carrera; Walter Wahli
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

4.  Fibrates for the Treatment of Primary Biliary Cholangitis Unresponsive to Ursodeoxycholic Acid: An Exploratory Study.

Authors:  Guilherme Grossi Lopes Cançado; Cláudia Alves Couto; Laura Vilar Guedes; Michelle Harriz Braga; Débora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado; Maria Lucia Gomes Ferraz; Cristiane Alves Villela-Nogueira; Mateus Jorge Nardelli; Luciana Costa Faria; Elze Maria Gomes de Oliveira; Vivian Rotman; Daniel Ferraz de Campos Mazo; Valéria Ferreira de Almeida E Borges; Liliana Sampaio Costa Mendes; Liana Codes; Mario Guimarães Pessoa; Izabelle Venturini Signorelli; Cynthia Levy; Paulo Lisboa Bittencourt
Journal:  Front Pharmacol       Date:  2022-01-20       Impact factor: 5.810

Review 5.  Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity.

Authors:  Bin Tu; Yanrong Gao; Feifei Sun; Mingjie Shi; Yongzhuo Huang
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

Review 6.  PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.

Authors:  Naomi F Lange; Vanessa Graf; Cyrielle Caussy; Jean-François Dufour
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

7.  Frontiers in metabolic physiology grand challenges.

Authors:  John D Imig
Journal:  Front Physiol       Date:  2022-08-10       Impact factor: 4.755

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.